TY - JOUR
T1 - Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome
T2 - A Consensus Statement of the CurePSP Centers of Care
AU - Bluett, Brent
AU - Pantelyat, Alexander Y.
AU - Litvan, Irene
AU - Ali, Farwa
AU - Apetauerova, Diana
AU - Bega, Danny
AU - Bloom, Lisa
AU - Bower, James
AU - Boxer, Adam L.
AU - Dale, Marian L.
AU - Dhall, Rohit
AU - Duquette, Antoine
AU - Fernandez, Hubert H.
AU - Fleisher, Jori E.
AU - Grossman, Murray
AU - Howell, Michael
AU - Kerwin, Diana R.
AU - Leegwater-Kim, Julie
AU - Lepage, Christiane
AU - Ljubenkov, Peter Alexander
AU - Mancini, Martina
AU - McFarland, Nikolaus R.
AU - Moretti, Paolo
AU - Myrick, Erica
AU - Patel, Pritika
AU - Plummer, Laura S.
AU - Rodriguez-Porcel, Federico
AU - Rojas, Julio
AU - Sidiropoulos, Christos
AU - Sklerov, Miriam
AU - Sokol, Leonard L.
AU - Tuite, Paul J.
AU - VandeVrede, Lawren
AU - Wilhelm, Jennifer
AU - Wills, Anne Marie A.
AU - Xie, Tao
AU - Golbe, Lawrence I.
N1 - Funding Information:
The authors thank CurePSP for administrative support. Funding. The publication fee will be paid by CurePSP, New York, NY, USA.
Publisher Copyright:
© Copyright © 2021 Bluett, Pantelyat, Litvan, Ali, Apetauerova, Bega, Bloom, Bower, Boxer, Dale, Dhall, Duquette, Fernandez, Fleisher, Grossman, Howell, Kerwin, Leegwater-Kim, Lepage, Ljubenkov, Mancini, McFarland, Moretti, Myrick, Patel, Plummer, Rodriguez-Porcel, Rojas, Sidiropoulos, Sklerov, Sokol, Tuite, VandeVrede, Wilhelm, Wills, Xie and Golbe.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS; the most common phenotype of corticobasal degeneration) are tauopathies with a relentless course, usually starting in the mid-60s and leading to death after an average of 7 years. There is as yet no specific or disease-modifying treatment. Clinical deficits in PSP are numerous, involve the entire neuraxis, and present as several discrete phenotypes. They center on rigidity, bradykinesia, postural instability, gait freezing, supranuclear ocular motor impairment, dysarthria, dysphagia, incontinence, sleep disorders, frontal cognitive dysfunction, and a variety of behavioral changes. CBS presents with prominent and usually asymmetric dystonia, apraxia, myoclonus, pyramidal signs, and cortical sensory loss. The symptoms and deficits of PSP and CBS are amenable to a variety of treatment strategies but most physicians, including many neurologists, are reluctant to care for patients with these conditions because of unfamiliarity with their multiplicity of interacting symptoms and deficits. CurePSP, the organization devoted to support, research, and education for PSP and CBS, created its CurePSP Centers of Care network in North America in 2017 to improve patient access to clinical expertise and develop collaborations. The directors of the 25 centers have created this consensus document outlining best practices in the management of PSP and CBS. They formed a writing committee for each of 12 sub-topics. A 4-member Steering Committee collated and edited the contributions. The result was returned to the entire cohort of authors for further comments, which were considered for incorporation by the Steering Committee. The authors hope that this publication will serve as a convenient guide for all clinicians caring for patients with PSP and CBS and that it will improve care for patients with these devastating but manageable disorders.
AB - Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS; the most common phenotype of corticobasal degeneration) are tauopathies with a relentless course, usually starting in the mid-60s and leading to death after an average of 7 years. There is as yet no specific or disease-modifying treatment. Clinical deficits in PSP are numerous, involve the entire neuraxis, and present as several discrete phenotypes. They center on rigidity, bradykinesia, postural instability, gait freezing, supranuclear ocular motor impairment, dysarthria, dysphagia, incontinence, sleep disorders, frontal cognitive dysfunction, and a variety of behavioral changes. CBS presents with prominent and usually asymmetric dystonia, apraxia, myoclonus, pyramidal signs, and cortical sensory loss. The symptoms and deficits of PSP and CBS are amenable to a variety of treatment strategies but most physicians, including many neurologists, are reluctant to care for patients with these conditions because of unfamiliarity with their multiplicity of interacting symptoms and deficits. CurePSP, the organization devoted to support, research, and education for PSP and CBS, created its CurePSP Centers of Care network in North America in 2017 to improve patient access to clinical expertise and develop collaborations. The directors of the 25 centers have created this consensus document outlining best practices in the management of PSP and CBS. They formed a writing committee for each of 12 sub-topics. A 4-member Steering Committee collated and edited the contributions. The result was returned to the entire cohort of authors for further comments, which were considered for incorporation by the Steering Committee. The authors hope that this publication will serve as a convenient guide for all clinicians caring for patients with PSP and CBS and that it will improve care for patients with these devastating but manageable disorders.
KW - CurePSP
KW - consensus
KW - corticobasal syndrome
KW - management
KW - palliative
KW - progressive supranuclear palsy
KW - symptomatic
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85110598171&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110598171&partnerID=8YFLogxK
U2 - 10.3389/fneur.2021.694872
DO - 10.3389/fneur.2021.694872
M3 - Review article
AN - SCOPUS:85110598171
SN - 1664-2295
VL - 12
JO - Frontiers in Neurology
JF - Frontiers in Neurology
M1 - 694872
ER -